ADVANCED HODGKIN LYMPHOMA - A RISK STRATIFICATION OF ABVD TREATED FEMALES IN GENERATIVE AGE

被引：0
|
作者：
Andjelic, B. [1 ,2 ]
Jakovic, L. J. [1 ]
Antic, D. [1 ,2 ]
Todorovic, M. [1 ,2 ]
Bila, J. [1 ,2 ]
Djurasinovic, V. [1 ]
Sretenovic, A. [1 ]
Vukovic, V. [1 ]
Jelicic, J. [1 ]
Smiljanic, M. [1 ]
Mihaljevic, B. [1 ,2 ]
机构：
[1] Clin Ctr Serbia, Clin Hematol, Belgade, Serbia
[2] Univ Belgrade, Fac Med, Belgrade, Serbia
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P017
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [31] Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin's lymphoma: A retrospective analysis
    Tao, Yun-xia
    Sun, San-yuan
    Kang, Su-yi
    Zhou, Li-qiang
    Shi, Yuan-kai
    Li, Ye-xiong
    Sun, Yan
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2014, 34 (02) : 260 - 264
  • [32] Comparison of Dose-dense ABVD and Standard ABVD in the Treatment of Early Unfavorable and Advanced Hodgkin's Lymphoma: A Retrospective Analysis
    陶云霞
    孙三元
    康愫意
    周立强
    石远凯
    李晔雄
    孙燕
    Current Medical Science, 2014, (02) : 260 - 264
  • [33] Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin’s lymphoma: A retrospective analysis
    Yun-xia Tao
    San-yuan Sun
    Su-yi Kang
    Li-qiang Zhou
    Yuan-kai Shi
    Ye-xiong Li
    Yan Sun
    Journal of Huazhong University of Science and Technology [Medical Sciences], 2014, 34 : 260 - 264
  • [34] Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy
    Fernandez-Alvarez, Ruben
    Gonzalez-Rodriguez, Ana P.
    Esther Gonzalez, M.
    Rubio-Castro, Arturo
    Dominguez-Iglesias, Francisco
    Solano, Jackeline
    Alonso-Nogues, Eva
    Fernandez-Alvarez, Carmen
    Zanabili, Yahya
    Manuel Alonso, Jose
    Ramirez Payer, Angel
    Maria Vicente, Jose
    Medina, Jesus
    Sancho, Juan M.
    LEUKEMIA & LYMPHOMA, 2015, 56 (11) : 3096 - 3102
  • [35] ABVD as the Treatment Option in Advanced Hodgkin's Lymphoma Patients Older than 45 Years
    Andjelic, Bosko M.
    Mihaljevic, Biljana S.
    Jakovic, Ljubomir R.
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (03) : 675 - 680
  • [36] Damage to ovarian functions in young women treated with ABVD and BEACOPP chemotherapy for Hodgkin's lymphoma
    Smardova, L
    Kral, Z
    Vasova, I
    Wagnerova, B
    Vorlicek, J
    ANNALS OF ONCOLOGY, 2005, 16 : 118 - 119
  • [37] PET2-Adapted Therapy in Patients With Advanced-Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater
    Pinto, Antonio
    Cuccaro, Annarosa
    Bonanni, Matteo
    Fresa, Alberto
    Filippi, Rosaria De
    Corazzelli, Gaetano
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
  • [38] Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study
    Makiyama, Junya
    Imaizumi, Yoshitaka
    Watanabe, Haruka
    Fujioka, Machiko
    Chiwata, Masahiko
    Kitanosono, Hideaki
    Nakashima, Jun
    Miyazaki, Yasushi
    Yoshida, Shinichiro
    INTERNAL MEDICINE, 2021, 60 (05) : 709 - 718
  • [39] Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma
    D'Arco, Alfonso Maria
    Califano, Catello
    Barone, Lucia
    Petrizzi, Valeria Belsito
    Iovino, Vincenzo
    Langella, Maria
    Maglione, Valentina
    Rivellini, Flavia
    De Lorenzo, Sonya
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (04) : 662 - 665
  • [40] Bleomycin pulmonary toxicity in Hodgkin's lymphoma treated with ABVD regimen not followed by radiation.
    Rajendran, Tara
    Prasad, Krishna
    CLINICAL CANCER RESEARCH, 2017, 23 (24) : 56 - 57
12345